AlphAIAlphAI — Financial news for AI agents
tipranks.comOCT 232 min read$ABBV

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi for Crohn’s

AbbVie (ABBV) announced FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn’s disease, allowing at-home treatment initiation. The company highlights improved patient flexibility and treatment efficacy. Recent analyst actions include price target adjustments and rating changes for ABBV and Avalo Therapeutics.

Original reporting
tipranks.com
Published Oct 23, 2026, 7:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 4:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The FDA clearance is expected to broaden the drug's patient base and improve adherence, supporting revenue forecasts.

02

Market read

First‑report FDA approval for a new dosing regimen of an existing drug, likely to move AbbVie stock positively.

03

What to watch

Potential competition from biosimilars and payer coverage decisions could temper upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Skyrizi is AbbVie's IL‑23 inhibitor already approved for ulcerative colitis; this adds a home‑administered induction option for Crohn's disease.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

FDA approval of a subcutaneous induction regimen for Skyrizi in Crohn's disease.

Expected impact

upward pressure as investors price in new market opportunity

Evidence & confidence

Regulatory clearance is a material catalyst for a late‑stage drug; market typically reacts positively.

Market effects

Sector

Biopharma sector may see uplift as the approval highlights subcutaneous delivery trends.

Regional

U.S. biotech stocks could benefit from the news, with limited immediate effect abroad.

Global

Adds to global confidence in IBD therapeutics, but primary impact is U.S. focused.

Counterpoint

What could challenge this read

If pricing or reimbursement issues arise, the approval may not translate into revenue growth.

Key entities

  • Company
    AbbVie

    Pharmaceutical company developing Skyrizi.

  • Regulator
    FDA

    U.S. Food and Drug Administration granting approval.

Read at source← All news

StoryFDA approves at‑home subcutaneous induction regimen for AbbVie’s SKYRIZI in Crohn’s disease

Also covered by

6 outlets

Related articles

OCT 24
$ABBVMed

AbbVie Won FDA Approval for At-Home Skyrizi Starts in Crohn’s. Here’s When It Should Show Up in Sales

AbbVie (ABBV) received FDA approval for at-home Skyrizi starts in Crohn's disease, potentially boosting sales. The approval allows patients to begin treatment at home with an on-body injector. Shares closed at $285.64 on October 23. Third-quarter results are due on October 30, with revenue guidance around $17.2 billion. Analysts expect a potential total return of ~27% with a target price of ~$364.

finance.yahoo.com3 min
OCT 23
$ABBVHigh

Abbvie Announces U.S. Fda Approval of Subcutaneous Induction Regimen for Skyrizi for Adults with Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval follows positive Phase 3 trial results, showing significant clinical remission and endoscopic response in patients. SKYRIZI can now be administered at home using an on-body injector, with induction doses at weeks 0, 2, 4, and 8, followed by maintenance dosing every eight weeks.

marketscreener.com2 min
OCT 23
$ABBVHigh

AbbVie (ABBV) Gains FDA Nod for At-Home Skyrizi Induction in Cro

AbbVie (ABBV) received FDA approval for an at-home subcutaneous induction regimen for its drug Skyrizi, allowing adults with moderate to severe Crohn’s disease to start treatment at home. The company offers a 2.34% dividend yield with a high payout ratio of 85% and a 3-year dividend growth rate of 5.2%. AbbVie's GF Value™ suggests the stock is modestly overvalued at $222.72 versus the current price of $286.20.

gurufocus.com3 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SK

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on positive Phase 3 AFFIRM trial results, showing superior clinical remission and endoscopic response at week 12 compared to placebo, especially in treatment-naïve patients. The subcutaneous form allows for at-home administration using an on-body injector.

gurufocus.com2 min